Gilead clinical trials for coronavirus treatment remdesivir - Business Insider
Companies, agencies, institutions, etc
Gilead Sciences
The National Institutes of Health's
COVID-19
drug's
The New England Journal of Medicine
the World Health Organization
CNN
Digital Health Articles
Value-Based Care Model
Wearable Tech
Healthcare
- Remote Patient Monitoring Industry
People
Merdad Parsey
Bruce Aylward
Groups
Asian
Physical locations
No matching tags
Places
No matching tags
Locations
China
US
Healthcare
Events
No matching tags
Summary
The studies will assess different doses and treatment courses of the experimental antiviral medication remdesivir in about 1,000 patients with COVID-19.A sense of urgency has been placed on the drug industry to identify and develop vaccines and treatments to halt the coronavirus outbreak that has killed more than 2,700 people and sickened more than 81,000. Here's how 6 top drugmakers are racing to tackle an outbreak that's spreading around the world."Gilead's primary focus is on rapidly determining the safety and efficacy of remdesivir as a potential treatment for COVID-19, and this complementary array of studies helps to give us a more expansive breadth of data globally on the drug's profile in a short amount of time," Merdad Parsey, Gilead's chief medical officer, said in a statement.
As said here by Andrew Dunn